Freddy Jimenez Increases Stake in Celldex Therapeutics

Freddy Jimenez, Senior Vice President and General Counsel at Celldex Therapeutics, Inc. (NasdaqCM: CLDX), made a notable move by purchasing 93,000 shares of the company on June 25, 2026. This transaction wasn't part of a pre-planned trading program, indicating a personal vote of confidence in the company's future.

Celldex Therapeutics, Inc. Stock Down 9.9%

Shares of Celldex Therapeutics traded near $35.26 on Tuesday. The company, which operates in the biotechnology sector, has a market cap of approximately $2.77 billion. Despite reporting a negative forward P/E ratio due to unprofitability, the stock has shown strength with a 52-week high of $35.79 and a 52-week low of $19.52. Its 50-day moving average stands at $32.10, while the 200-day moving average is $28.27. Celldex maintains a strong liquidity position with a current ratio of 8.92 and a quick ratio of 8.78.

Insider Buying and Selling at Celldex Therapeutics, Inc.

On the same day as Jimenez's purchase, several other insiders at Celldex Therapeutics also acquired shares. Ronald Pepin, Senior Vice President and Chief Business Officer, bought 20,000 shares. Denice Torres and Garry Arthur Neil, whose titles were not specified, each purchased 26,000 shares. Samuel Bates, Senior Vice President and CFO, acquired 93,000 shares, while Margo Heath-Chiozzi, Senior Vice President of Regulatory Affairs, and Sarah Cavanaugh, Senior Vice President of Corporate Affairs & Administration, each bought 95,000 shares.

Analysts Set New Price Targets

Analysts have been optimistic about Celldex Therapeutics, with multiple firms maintaining or reiterating buy ratings. On June 15, 2026, HC Wainwright & Co. reiterated its buy rating with a $42.00 price target. UBS maintained a buy rating with a $45.00 target on June 10, while Wells Fargo kept its buy rating with a $54.00 target on May 13. The consensus among 15 analysts is a strong buy, with a mean price target of $57.53.

About Celldex Therapeutics

Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey. It focuses on developing therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. The company's pipeline includes Barzolvolimab (CDX-0159), targeting chronic urticarias and other conditions, and CDX-622, which addresses chronic inflammation. Led by CEO Anthony S. Marucci, the company employs 198 people.

Bottom Line

Freddy Jimenez's purchase of 93,000 shares in Celldex Therapeutics underscores his confidence in the company's trajectory. While insider buying can indicate positive sentiment, investors should consider the broader financial context. With a strong liquidity position and supportive analyst ratings, Celldex remains a company to watch in the biotechnology sector.